Translate
Travere Therapeutics Inc
About
Travere Therapeutics Inc (NASDAQ:TVTX) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 13 2026
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS
Feb 19 2026
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Feb 12 2026
Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
Feb 4 2026
Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit
Jan 13 2026
Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS
Financials
Revenue
$490.73 M
Market Cap
$2.81 B
EPS
-0.57